Novo Nordisk Lifts 2026 Guidance as Wegovy Pill Sales Top Forecasts — BigGo Finance
Novo Nordisk A/S (NVO) raised its full-year outlook for the second time in three months on Wednesday, after…
![[Novo Nordisk A/S Q3 2026 Earnings Call] Novo Nordisk Lifts Guidance Again as Q3 Sales Rise 4% and Operating Profit Jumps 27%; CFO Exits After 27 Years](https://www.europesays.com/dk/wp-content/uploads/2026/11/aHR0cHM6Ly9pbWcuYmdvLm9uZS9uZXdzLWltYWdlL2Vhcm5pbmdzX2NhcmQvMjAyNi0xMS9VU19OVk9fMjAyNi0xMS0wNF8xNzkz-380x220.jpeg)
[Novo Nordisk A/S Q3 2026 Earnings Call] Novo Nordisk Lifts Guidance Again as Q3 Sales Rise 4% and Operating Profit Jumps 27%; CFO Exits After 27 Years
Novo Nordisk Lifts Guidance Again as Q3 Sales Rise 4% and Operating Profit Jumps 27%; CFO Exits After…
Novo Nordisk Says Switching to Oral Wegovy Kept Patients Losing Weight — BigGo Finance
Patients who traded their weight-loss injections for Novo Nordisk’s once-daily pill kept shedding pounds, according to new data…
Wegovy Maker Novo Nordisk Partners With Anthropic to Deploy Claude AI
Novo Nordisk NOVO.B -2.53%decrease; down pointing triangle, the Danish drugmaker behind blockbuster diabetes and weight-loss drugs Ozempic and…
Novo Nordisk stock falls after 2030 strategy disappoints investors
Novo set out its 2030 strategic ambitions at a Capital Markets Day in London on Monday, but the…
Novo Nordisk Weighs Direct NYSE Listing as U.S. Investors Push for Closer Access — BigGo Finance
Novo Nordisk (NVO) is exploring the possibility of moving its U.S. listing from American depositary receipts to a…
NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
On Wednesday, CEO Mike Doustdar told the Financial Times that Novo is open to a direct NYSE listing…
Accenture Up on Partnership with Anthropic; Novo Nordisk Falls on Turnaround
00:00 Alexis Christopherus We are, we’re changing it up. 00:01 Tom Gunn Changing it up, really. 00:02 Alexis…
Novo Nordisk stock gets drilled on pipeline concerns — its CEO sees a main problem
Novo Nordisk (NVO) shares are slimming down. Shares of the Wegovy maker tanked more than 4% on Monday…
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT
Sept 23 (Reuters) – Novo Nordisk is open to the idea of upgrading its New York listing as…
Novo CEO says pills could capture 50% of weight-loss market by 2030
By Patrick Wingrove LONDON, Sept 22 – Weight-loss pills could capture as much as half of the global…
Novo’s CEO Called Ozempic’s Patent Cliff the “Elephant in the Room” Yesterday. Is the Stock Still a Buy?
Every pharmaceutical company dreams of having a pioneering blockbuster drug, i.e., one whose annual sales top $1 billion.…